pazopanib

pazopanib2016-11-15T13:27:46+00:00

pazopanib

ONCOLOGY, THERAPEUTICS

A therapeutic tyrosine kinase receptor inhibitor of angiogenesis, which acts on vascular endothelial growth factors VEGFR-1, VEGFR-2, and VEGFR-3, as well as PDGFR-a/β, and c-kit. It was approved by the FDA in 2012 for managing renal cell carcinoma and soft tissue sarcomas, and may be effective in ovarian cancer and non-small cell carcinoma of the lung.

Adverse effects Slow wound healing, dizziness, fainting, heart palpitations, fever, chills, easy bruising, flu-like symptoms, oropharyngeal sores, dyspnoea, oedema rapid weight gain, oral and GI tract bleeding, nausea, stomach ache, convulsions, episodic hypertension, and haematemesis. 

Brand name Votrient 

References http://en.wikipedia.org/wiki/Pazopanib

http://www.drugs.com/sfx/pazopanib-side-effects.html

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.